Applying bacteria to your face may not seem like the most effective way to improve your skin and yethas set out to do just that.
The AIM-listed life sciences company is initially targeting the cosmetic skin care market with its microbiome skin-health technology, however, it has plans to use the applications in anti-infectives and dermatological indications (eczema).
It turns out the bacteria, fungi, viruses and other microbes that make up the microbiome, are very useful to the body - among many other things, they programme the immune system, provide nutrients for our cells and prevent colonisation by harmful bacteria and viruses.
The microbiome is an exciting and growing area of science, with research continuing to emerge. SkinBioTherapeutics was in fact formed as a spin-out from the University of Manchester, with the scientific discoveries forming its proprietary SkinBiotix® technology, thanks to the work of CEO Dr. Catherine O'Neill, and Professor Andrew McBain.
SkinBiotix® uses extracts taken from beneficial bacteria and has been shown to enhance moisturisation, prevent infection and improve skin barrier function. It began human trials for the cosmetic applications of Skinbiotix technology in September, after passing multiple key cytotoxicity tests. Most notably, however, it has successfully demonstrated that the lysate can be freeze-dried and scaled-up to industrial levels.
The global skin care product market generated revenues of $136 billion in 2016 and is expected to grow to reach $194 billion by 2024, according to Allied Research. This is driven largely by rising demand for natural skin care products and a growing emphasis on personal health, especially in the developing countries of Asia Pacific.
The company hopes to tap into some of this vast market share, and major FMCG and cosmetic companies have already expressed interest in its proprietary technology. One major global consumer goods company entered into a material transfer agreement in April this year (standard agreement enabling it to access the technology), which if successful, can be a precursor to future commercial arrangements.
Although it is in its early stages of development, the company may have an early mover advantage in the potentially high growth market of probiotic skin health. Since 2010, microbiome companies have attracted around US$840mln in equity investments globally, according to Northland Capital.
Shares in SkinBioTherapeutics were trading at 16.75p each
The main element of the human study is set to begin later this month, which will comprise of 120 volunteers to analyse the longer-term moisturisation effects and impact on skin barrier function of the SkinBiotix® technology in more depth. Cosmetic studies are shorter than drug trials, which usually leads to a shorter path to commercialisation.
Northland Capital noted, “The completion of the human study is a key inflection point”. Should the data provide further proof of effectiveness, the cosmetic applications can be labelled ‘dermatologically tested’ and allowing SkinBioTherapeutics to pursue more commercial discussions with potential partners.
The Company is well positioned to take advantage if studies prove successful, as the Board has experience in fund-raising and early phase corporate development in life science listed companies, so far continuing to deliver on its objectives since IPO.
With a £19m market cap and a potential early mover advantage, opportunistic analysts and investors will be following the SkinBioTherapeutics story closely.
Follow News & Updates from SkinBioTherapeutics here:
easyJet boss Johan Lundgren says Brexit will be smooth for airline, US medical devices manufacturer Boston Scientific is seeking to buy British pharmaceutical firm BTG
Align note on PowerHouse Energy Pioneering waste-to-hydrogen tech provider now on the cusp of commercialisation & creating significant shareholder value
On today's podcast: Tlou Energy (TLOU) provides an update on the drilling operations at their Lesedi coal bed methane project and touches on other parts of the business. Emmerson (EML) discusses the results of its recently completed Scoping Study. Also Alan Green CEO of Brand Communications talks about: Itaconix (ITX) Cadence (KDNC) Griffin Mining (GFM).
Emmerson, has released the much anticipated Scoping Study for the company’s Khemisset Potash Project in northern Morocco, months ahead of schedule. “Khemisset, gives Emmerson a clear opportunity to be one of the few junior companies in the space.”
See Today's AIM Risers featuring Greatland Gold (GGP), Flananx Group (FLX), Physiomics (PYC) and Highland Natural Resources (HNR).
Tlou Energy has announced that their Lesedi drill programme, the company’s coal bed methane project in Botswana, is “making excellent progress and on budget.” Two vertical wells, Lesedi 3P and Lesedi 4P, have completed drilling and work has already begun on a third vertical well, Lesedi 5P.
Shares on Wall Street tank as some of America's biggest tech companies take a hammering from investors, Pension Protection Fund raises concerns over Johnston Press collapse, Corporate raider targeting Barclays expected to demand seat on board in coming weeks
Five financial stories, trending today in a 70 second podcast, including: Shares in some of the world's largest technology stocks plunged yesterday, dragging the Nasdaq down by 3% to drive a wider market sell-off.
Car crash for Nissan as chairman Carlos Ghosn fired for pay ‘misconduct’, Troubled TSB hires CYBG (CYBG) veteran Debbie Crosbie to replace outgoing boss Paul Pester as bank tries to turn fortunes around after IT debacle
On today's podcast: Neill Ricketts, Chief Executive Officer of Versarien (VRS) discusses their plans to establish a manufacturing centre in the Jinan Innovation Zone, Shandong Province of China. Plus oil & gas sector specialist Malcy talks about the following stocks: Sound Energy (SOU) Premier Oil (PMO) President Energy (PPC) Faroe Petroleum (FPM) Empyrean Energy (EME)